ストックスクリーナーアプリを入手
34.28
2.12%
0.758
前日終値:
$33.52
開ける：
$33.92
24時間の取引高:
415.94K
Relative Volume:
0.18
時価総額：
$5.66B
収益：
$1.51B
当期純損益:
$333.35M
株価収益率:
17.58
EPS:
1.95
ネットキャッシュフロー:
$315.22M
1週間 パフォーマンス:
+1.12%
1か月 パフォーマンス:
+20.15%
6か月 パフォーマンス:
+30.90%
1年 パフォーマンス:
+9.54%
1日の値動き範囲:
$33.55
$34.30
1週間の範囲:
$32.49
$34.67
52週間の値動き範囲:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
ALKS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
34.27 | 5.53B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
123.27 | 55.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.73 | 53.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.34 | 46.40B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.74 | 37.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.00 | 20.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-11 | 開始されました | Truist | Buy |
| 2025-09-26 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 開始されました | Wells Fargo | Overweight |
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2025-06-17 | アップグレード | UBS | Neutral → Buy |
| 2025-05-28 | 開始されました | Needham | Buy |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | アップグレード | UBS | Sell → Neutral |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-11-05 | アップグレード | Stifel | Hold → Buy |
| 2024-06-17 | 開始されました | TD Cowen | Buy |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-20 | ダウングレード | UBS | Neutral → Sell |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-24 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 開始されました | UBS | Neutral |
| 2022-11-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 開始されました | Piper Sandler | Neutral |
| 2022-04-22 | 再開されました | Goldman | Buy |
| 2022-04-20 | 開始されました | Goldman | Buy |
| 2022-01-27 | アップグレード | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 開始されました | Citigroup | Neutral |
| 2021-10-07 | アップグレード | Jefferies | Hold → Buy |
| 2021-09-02 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-10-15 | アップグレード | Mizuho | Neutral → Buy |
| 2020-07-30 | ダウングレード | Goldman | Neutral → Sell |
| 2020-02-14 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-01-31 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-31 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-12-19 | ダウングレード | Goldman | Neutral → Sell |
| 2018-12-14 | 開始されました | Wolfe Research | Underperform |
| 2018-12-13 | ダウングレード | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 開始されました | Piper Jaffray | Neutral |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | アップグレード | Citigroup | Neutral → Buy |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Alkermes Plc (ALKS) 最新ニュース
Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal - Investing.com
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Why analysts are rating Alkermes (ALKS) a buy - MSN
Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One" - Finviz
Jim Cramer on Alkermes: “I Think It’s a Hold, Maybe a Weak One” - Insider Monkey
Weekly Earnings: Is Alkermes plc benefiting from interest rate changesQuarterly Trade Report & Verified Entry Point Detection - baoquankhu1.vn
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies - Finviz
Campbell & CO Investment Adviser LLC Has $741,000 Position in Alkermes plc $ALKS - MarketBeat
Precision Trading with Alkermes Plc (ALKS) Risk Zones - Stock Traders Daily
Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good' - Sahm
Avadel Sets Court Date for Alkermes Acquisition Scheme - TipRanks
Avadel (NASDAQ: AVDL) moves Alkermes acquisition forward with Irish court hearing date - Stock Titan
ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results - Finviz
Alkermes (ALKS) Is Up 6.8% After FDA Breakthrough Tag for Narcolepsy Drug Candidate AlixorextonWhat's Changed - simplywall.st
Aug Outlook: Is Braemar Hotels Resorts Inc part of any ETF2025 Trading Recap & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development - Intellectia AI
Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton - Yahoo Finance
Rate Cut: What analysts say about Alkermes plc stockTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Aug Final Week: Is Alkermes plc benefiting from interest rate changesJobs Report & Short-Term High Return Ideas - baoquankhu1.vn
Recap Report: Can Alkermes plc stock outperform in a bear market - baoquankhu1.vn
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Finviz
ALKS: RBC Capital Raises Price Target to $47, Maintains 'Outperf - GuruFocus
Piper Sandler Raises Price Target for ALKS to $45, Reiterates Ov - GuruFocus
Are Medical Stocks Lagging Alkermes (ALKS) This Year? - sharewise.com
Avadel Pharmaceuticals shareholders approve $2.37B takeover bid - The Business Journals
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz
Alkermes PLC (ALKS) Stock Price Up 3.16% on Jan 15 - GuruFocus
Alkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Alkermes plc (NASDAQ:ALKS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? - Finviz
Best Value Stocks to Buy for Jan.14 - The Globe and Mail
Update Report: Can inTEST Corporation scale operations efficientlySell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Improved Earnings Required Before Alkermes Plc (NASDAQ:ALKS) Shares Find Their Feet - 富途牛牛
Aug Rallies: Will Alkermes plc stock remain a Wall Street favorite2025 Volume Leaders & Momentum Based Trading Ideas - Bộ Nội Vụ
Retail Trends: Can Alkermes plc stock deliver 10 annual returnsInsider Selling & Precise Trade Entry Recommendations - Bộ Nội Vụ
Avadel Shareholders Approve Acquisition by Alkermes - Sleep Review
Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close - Yahoo Finance
ALKS: ALKS 2680 advances to Phase 3, targeting major sleep disorders and expanding commercial reach - TradingView — Track All Markets
ALKS: ALKS 2680 advances as a potential blockbuster, driving growth and sleep medicine expansion - TradingView — Track All Markets
Avadel shareholders approve acquisition by Alkermes - Investing.com Nigeria
Alkermes (ALKS) Secures Shareholder Approval for Avadel Acquisition - GuruFocus
Avadel shareholders approve acquisition by Alkermes By Investing.com - Investing.com South Africa
Avadel Shareholders Approve Acquisition by Alkermes plc - TipRanks
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes - The Manila Times
Avadel Pharmaceuticals plc Approves Scheme of Arrangement for Alkermes Acquisition - Quiver Quantitative
Shareholders back Avadel sale to Alkermes after strong vote - Stock Titan
Alkermes plans Avadel acquisition to expand sleep portfolio - TipRanks
Alkermes plc (ALKS): Investor Outlook Reveals 47.29% Potential Upside Amid Robust Product Pipeline - DirectorsTalk Interviews
How to contact the Daily Bulletin - FinancialContent
Buybacks Report: What dividend safety score for Alkermes plc stock2025 Key Highlights & Smart Swing Trading Techniques - Bộ Nội Vụ
Alkermes Plc (ALKS) 財務データ
収益
当期純利益
現金流量
EPS
2.59%
1.57%
大文字化:
|
ボリューム (24 時間):